Julian Topaly

1.1k total citations
31 papers, 848 citations indexed

About

Julian Topaly is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Julian Topaly has authored 31 papers receiving a total of 848 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 15 papers in Genetics and 11 papers in Oncology. Recurrent topics in Julian Topaly's work include Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (10 papers). Julian Topaly is often cited by papers focused on Chronic Myeloid Leukemia Treatments (15 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (10 papers). Julian Topaly collaborates with scholars based in Germany, United Kingdom and United States. Julian Topaly's co-authors include Stefan Früehauf, Anthony D. Ho, Marlon R. Veldwijk, W. Jens Zeller, W. Jens Zeller, Stephanie Laufs, Frederik Wenz, Hartmut Goldschmidt, Ulrich R. Hengge and Aleksandar Radujkovic and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Julian Topaly

30 papers receiving 828 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julian Topaly Germany	15	522	291	240	194	163	31	848
Anna Jankowska United States	15	494 0.9×	324 1.1×	390 1.6×	185 1.0×	69 0.4×	27	939
Odile Maarek France	13	645 1.2×	411 1.4×	352 1.5×	267 1.4×	231 1.4×	24	1.0k
BA Zehnbauer United States	11	830 1.6×	402 1.4×	277 1.2×	216 1.1×	123 0.8×	14	1.1k
CJ Eaves Canada	6	549 1.1×	273 0.9×	159 0.7×	202 1.0×	82 0.5×	8	721
Antonella Zagaria Italy	23	637 1.2×	403 1.4×	504 2.1×	132 0.7×	98 0.6×	80	1.2k
Luisa Anelli Italy	23	693 1.3×	436 1.5×	563 2.3×	149 0.8×	101 0.6×	87	1.3k
Marianne Rissler Sweden	15	565 1.1×	187 0.6×	322 1.3×	212 1.1×	84 0.5×	32	1.0k
Masaaki Takatoku Japan	18	658 1.3×	327 1.1×	528 2.2×	323 1.7×	39 0.2×	47	1.1k
Anita Badbaran Germany	23	972 1.9×	589 2.0×	570 2.4×	419 2.2×	235 1.4×	72	1.5k
Niove E. Jordanides United Kingdom	9	864 1.7×	636 2.2×	291 1.2×	221 1.1×	366 2.2×	13	1.2k

Countries citing papers authored by Julian Topaly

Since Specialization

Citations

This map shows the geographic impact of Julian Topaly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julian Topaly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julian Topaly more than expected).

Fields of papers citing papers by Julian Topaly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julian Topaly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julian Topaly. The network helps show where Julian Topaly may publish in the future.

Co-authorship network of co-authors of Julian Topaly

This figure shows the co-authorship network connecting the top 25 collaborators of Julian Topaly. A scholar is included among the top collaborators of Julian Topaly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julian Topaly. Julian Topaly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Welslau, Manfred, et al.. (2020). REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 38(15_suppl). 8060–8060. 2 indexed citations

2.

Radujkovic, Aleksandar, Thomas Luft, Peter Dreger, et al.. (2014). In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology. 74(2). 427–432. 2 indexed citations

3.

Sellner, Leopold, Marlon R. Veldwijk, Jürgen A. Kleinschmidt, et al.. (2011). Efficient gene transfer with pseudotyped recombinant adeno-associated viral vectors into human chronic myelogenous leukemia cells. Leukemia & lymphoma. 52(3). 483–490. 1 indexed citations

4.

Veldwijk, Marlon R., Leopold Sellner, Jürgen A. Kleinschmidt, et al.. (2009). Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34+ peripheral blood progenitor cells. Cytotherapy. 12(1). 107–112. 23 indexed citations

5.

Früehauf, Stefan, Gerhard Ehninger, Kai Hübel, et al.. (2009). Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplantation. 45(2). 269–275. 50 indexed citations

6.

Radujkovic, Aleksandar, Stefan Früehauf, W. Jens Zeller, Anthony D. Ho, & Julian Topaly. (2009). Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells. Cancer Chemotherapy and Pharmacology. 66(2). 255–264. 6 indexed citations

7.

Früehauf, Stefan, Marlon R. Veldwijk, Mario Schubert, et al.. (2009). A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy. 1–10. 6 indexed citations

8.

Früehauf, Stefan, Marlon R. Veldwijk, Mario Schubert, et al.. (2009). A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy. 11(8). 992–1001. 99 indexed citations

9.

Früehauf, Stefan, Julian Topaly, Eike C. Buss, et al.. (2007). Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 109(8). 1543–1549. 43 indexed citations

10.

Früehauf, Stefan, Johannes Huesing, Marlon R. Veldwijk, et al.. (2007). Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplantation. 39(12). 743–750. 36 indexed citations

11.

Radujkovic, Aleksandar, Julian Topaly, Stefan Früehauf, & W. Jens Zeller. (2006). Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.. PubMed. 26(3A). 2169–77. 15 indexed citations

12.

Radujkovic, Aleksandar, Julian Topaly, Marlon R. Veldwijk, et al.. (2005). Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG. Leukemia. 19(7). 1198–1206. 78 indexed citations

13.

Früehauf, Stefan, Thomas Seeger, & Julian Topaly. (2005). Innovative strategies for PBPC mobilization. Cytotherapy. 7(5). 438–446. 11 indexed citations

14.

Früehauf, Stefan, Julian Topaly, Peter Paschka, et al.. (2003). Imatinib restores expression of CD62L in BCR-ABL-positive cells. Journal of Leukocyte Biology. 73(5). 600–603. 12 indexed citations

15.

Topaly, Julian, Stefan Früehauf, Anthony D. Ho, & W. Jens Zeller. (2002). Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. British Journal of Cancer. 86(9). 1487–1493. 30 indexed citations

16.

Veldwijk, Marlon R., Julian Topaly, Stephanie Laufs, et al.. (2002). Development and Optimization of a Real-Time Quantitative PCR-Based Method for the Titration of AAV-2 Vector Stocks. Molecular Therapy. 6(2). 272–278. 98 indexed citations

17.

Topaly, Julian, W. Jens Zeller, & Stefan Früehauf. (2002). Combination therapy with imatinib mesylate (sti571): synopsis of in vitro studies. British Journal of Haematology. 119(1). 3–14. 27 indexed citations

18.

Früehauf, Stefan, et al.. (2002). Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.. PubMed. 87(12). ECR38–ECR38. 4 indexed citations

19.

Früehauf, Stefan, Stefanie Steiger, Julian Topaly, & H. F. A.. (2001). Pulmonary artery hypertension during interferon-α therapy for chronic myelogenous leukemia. Annals of Hematology. 80(5). 308–310. 28 indexed citations

20.

Früehauf, Stefan, Karin Schmitt, Marlon R. Veldwijk, et al.. (1999). Peripheral blood progenitor cell (PBPC) counts during steady‐state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony‐stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. British Journal of Haematology. 105(3). 786–794. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact